Numerous studies have shown the wide application of c-Met in digestive system cancers with related clinical and preclinical evidences supporting the anti-HGF/c-Met signaling pathway as a reliable treatment for HCC, gastric, pancreatic, and CRC among others. This evidence concerns the gene HGF and digestive system cancer.